FLT3 and acute myeloid leukemia: At initial AML diagnosis, patients with nucleophosmin 1 (NPM1) mutation without Fms-related receptor tyrosine kinase 3-internal tandem duplication (FLT3-ITD) are categorized as favorable, whereas mutated NPM1 along with FLT3-ITD are now classified as intermediate risk in the revised ELN risk classification [1].